Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.

Human pathology - 1 Oct 2017

Xing Deyin, Suryo Rahmanto Yohan, Zeppernick Felix, Hannibal Charlotte G, Kjaer Susanne K, Vang Russell, Shih Ie-Ming, Wang Tian-Li

Abstract excerpt

Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate during the progression of SBT to invasive low-grade serous carcinoma (LGSC) remains largely unknown. Although mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Baltimore
Share to Carcinoma
Share to Denmark

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Mutation Rate

Share to Neoplasm Grading

Share to Neoplasm Invasiveness

Share to Neoplasms, Cystic, Mucinous, and Serous

Source

Open in PubMed Open full text

Identifiers

PMID: 28873354
DOI: 10.1016/j.humpath.2017.08.021
PMCID: PMC5696063

Genes

NRAS
BRAF
KRAS
CGA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.PMID 28873354Read ↗

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Semantic proximity Read ↗

Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.Semantic proximity Read ↗

Somatic genetic alterations in synchronous and metachronous low‐grade serous tumours and high‐grade carcinomas of the adnexaSemantic proximity Read ↗

BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Semantic proximity Read ↗

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.Semantic proximity Read ↗

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.Semantic proximity Read ↗

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Semantic proximity Read ↗

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.Semantic proximity Read ↗

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.Semantic proximity Read ↗

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.